Soluble amyloid-ÃÂ² oligomers as synaptotoxins leadin AlzheimerÃ¢â‚¬â„¢s disease

Frontiers in Cellular Neuroscience

9, 191

DOI: 10.3389/fncel.2015.00191

Citation Report

#	Article	IF	Citations
1	Astaxanthin Protects Primary Hippocampal Neurons against Noxious Effects of AÎ²-Oligomers. Neural Plasticity, 2016, 2016, 1-13.	1.0	52
2	Multitarget Strategy to Address Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and Computational Studies of Coumarinâ€Based Derivatives. ChemMedChem, 2016, 11, 1296-1308.	1.6	20
3	Polymorphism of fibrillar structures depending on the size of assembled AÎ²17-42 peptides. Scientific Reports, 2016, 6, 38196.	1.6	19
4	Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases. Annual Review of Genetics, 2016, 50, 329-346.	3.2	53
5	The Associations between a Capsaicin-Rich Diet and Blood Amyloid-Î² Levels and Cognitive Function. Journal of Alzheimer's Disease, 2016, 52, 1081-1088.	1.2	36
6	Aberrant Co-localization of Synaptic Proteins Promoted by Alzheimerâ€™s Disease Amyloid-Î² Peptides: Protective Effect ofÂHuman Serum Albumin. Journal of Alzheimer's Disease, 2016, 55, 171-182.	1.2	18
7	Understanding the Role of miR-33 in Brain Lipid Metabolism: Implications for Alzheimer's Disease. Journal of Neuroscience, 2016, 36, 2558-2560.	1.7	16
8	Phosphorylation of the amyloid Î²-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. Acta Neuropathologica, 2016, 131, 525-537.	3.9	84
9	Protective effect of melatonin on soluble AÎ²1â€“42-induced memory impairment, astrogliosis, and synaptic dysfunction via the Musashi1/Notch1/Hes1 signaling pathway in the rat hippocampus. Alzheimer's Research and Therapy, 2016, 8, 40.	3.0	68
10	Synaptopathies: synaptic dysfunction in neurological disorders â€“ A review from students to students. Journal of Neurochemistry, 2016, 138, 785-805.	2.1	244
11	Do Microglia Default on Network Maintenance in Alzheimerâ€™s Disease?. Journal of Alzheimer's Disease, 2016, 51, 657-669.	1.2	17
12	Identifying N-linked glycan moiety and motifs in the cysteine-rich domain critical for N-glycosylation and intracellular trafficking of SR-AI and MARCO. Journal of Biomedical Science, 2016, 23, 27.	2.6	8
13	Cortical Astrocytes Acutely Exposed to the Monomethylarsonous Acid (MMAIII) Show Increased Pro-inflammatory Cytokines Gene Expression that is Consistent with APP and BACE-1: Over-expression. Neurochemical Research, 2016, 41, 2559-2572.	1.6	15
14	Ion channel regulation by Î²-secretase BACE1 â€“ enzymatic and non-enzymatic effects beyond Alzheimer's disease. Channels, 2016, 10, 365-378.	1.5	26
15	Comparative pathobiology of Î²-amyloid and the unique susceptibility of humans to Alzheimer's disease. Neurobiology of Aging, 2016, 44, 185-196.	1.5	34
16	Experience-dependent reduction of soluble Î²-amyloid oligomers and rescue of cognitive abilities in middle-age Ts65Dn mice, a model of Down syndrome. Experimental Neurology, 2016, 283, 49-56.	2.0	26
17	Kinesinâ€1 inhibits the aggregation of amyloidâ€Î² peptide as detected by fluorescence crossâ€correlation spectroscopy. FEBS Letters, 2016, 590, 1028-1037.	1.3	8
18	Atorvastatin ameliorates cognitive impairment, AÎ²1-42 production and Tau hyperphosphorylation in APP/PS1 transgenic mice. Metabolic Brain Disease, 2016, 31, 693-703.	1.4	15

#	Article	IF	Citations
19	Training Microglia to Resist Alzheimer's Disease. Journal of Neuroscience, 2017, 37, 477-479.	1.7	2
20	Real-Time Analysis of Binding Events between Different AÎ²_{1â€“42} Species and Human Lilrb2 by Dual Polarization Interferometry. Analytical Chemistry, 2017, 89, 2606-2612.	3.2	21
21	Reelin: Neurodevelopmental Architect and Homeostatic Regulator of Excitatory Synapses. Journal of Biological Chemistry, 2017, 292, 1330-1338.	1.6	98
22	Interaction of amyloid-Î² (AÎ²) oligomers with neurexin 2Î± and neuroligin 1 mediates synapse damage and memory loss in mice. Journal of Biological Chemistry, 2017, 292, 7327-7337.	1.6	67
23	Olfactory bulbectomy in mice triggers transient and long-lasting behavioral impairments and biochemical hippocampal disturbances. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 76, 1-11.	2.5	26
24	Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimerâ€™s disease. Acta Neuropathologica, 2017, 133, 933-954.	3.9	150
25	Focused ultrasound as a novel strategy for Alzheimer disease therapeutics. Annals of Neurology, 2017, 81, 611-617.	2.8	33
26	Neuroprotective effect of melatonin on soluble AÎ²_{1â€“42}-induced cortical neurodegeneration via Reelinâ€“Dab1 signaling pathway. Neurological Research, 2017, 39, 621-631.	0.6	16
27	Tau Spread, Apolipoprotein E, Inflammation, and More. Neurologic Clinics, 2017, 35, 175-190.	0.8	18
28	Chronic sleep restriction promotes brain inflammation and synapse loss, and potentiates memory impairment induced by amyloid-Î² oligomers in mice. Brain, Behavior, and Immunity, 2017, 64, 140-151.	2.0	89
29	Apomorphine Therapy for Neuronal Insulin Resistance in a Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 1151-1161.	1.2	25
30	The Alzheimerâ€™s disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons. Brain, 2017, 140, 2012-2027.	3.7	51
31	Multielement concentration analysis of Swiss mice brains on experimental model of Alzheimer's disease induced by Î²â€amyloid oligomers. X-Ray Spectrometry, 2017, 46, 397-402.	0.9	2
32	Cellular levels of growth factor receptor bound protein 2 (Grb2) and cytoskeleton stability are correlated in a neurodegenerative scenario. DMM Disease Models and Mechanisms, 2017, 10, 655-669.	1.2	13
33	Surface Assay for Specific Detection of Soluble Amyloid Oligomers Utilizing Pronucleon Peptides Instead of Antibodies. ACS Chemical Neuroscience, 2017, 8, 1213-1221.	1.7	6
34	Î±â€Synuclein Oligomers: A Study in Diversity. Israel Journal of Chemistry, 2017, 57, 699-723.	1.0	16
35	Endothelial LRP1 â€“ A Potential Target for the Treatment of Alzheimerâ€™s Disease. Pharmaceutical Research, 2017, 34, 2637-2651.	1.7	43
36	Taurine Directly Binds to Oligomeric Amyloid-Î² and Recovers Cognitive Deficits in Alzheimer Model Mice. Advances in Experimental Medicine and Biology, 2017, 975 Pt 1, 233-241.	0.8	44

#	Article	IF	Citations
37	Honokiol Attenuates Oligomeric Amyloid Î²1-42-Induced Alzheimerâ€™s Disease in Mice Through Attenuating Mitochondrial Apoptosis and Inhibiting the Nuclear Factor Kappa-B Signaling Pathway. Cellular Physiology and Biochemistry, 2017, 43, 69-81.	1.1	53
38	The AÎ² oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology. Scientific Reports, 2017, 7, 16275.	1.6	42
39	Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes. Neurobiology of Disease, 2017, 106, 76-88.	2.1	72
40	Inhibition of Alzheimer's amyloid-beta aggregation in-vitro by carbenoxolone: Insight into mechanism of action. Neurochemistry International, 2017, 108, 481-493.	1.9	34
41	PPAR Gamma Coactivator 1 Beta (PGC-1Î²) Reduces Mammalian Target of Rapamycin (mTOR) Expression via a SIRT1-Dependent Mechanism in Neurons. Cellular and Molecular Neurobiology, 2017, 37, 879-887.	1.7	11
42	BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimerâ€™s Disease Pathology. Molecules, 2017, 22, 1723.	1.7	89
43	Protein Tyrosine Phosphatase 1B (PTP1B): A Potential Target for Alzheimerâ€™s Therapy?. Frontiers in Aging Neuroscience, 2017, 9, 7.	1.7	80
44	The Biological Function of the Prion Protein: A Cell Surface Scaffold of Signaling Modules. Frontiers in Molecular Neuroscience, 2017, 10, 77.	1.4	105
45	Amyloid-Î² Impairs Vesicular Secretion in Neuronal and Astrocyte Peptidergic Transmission. Frontiers in Molecular Neuroscience, 2017, 10, 202.	1.4	9
46	Citalopram Ameliorates Impairments in Spatial Memory and Synaptic Plasticity in Female 3xTgAD Mice. BioMed Research International, 2017, 2017, 1-12.	0.9	21
47	Isoflurane anesthesia promotes cognitive impairment by inducing expression of Î²-amyloid protein-related factors in the hippocampus of aged rats. PLoS ONE, 2017, 12, e0175654.	1.1	30
48	Dietary arachidonic acid increases deleterious effects of amyloid-Î² oligomers on learning abilities and expression of AMPA receptors: putative role of the ACSL4-cPLA2 balance. Alzheimer's Research and Therapy, 2017, 9, 69.	3.0	16
49	Neurons derived from sporadic Alzheimerâ€™s disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation. Alzheimer's Research and Therapy, 2017, 9, 90.	3.0	161
50	Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimerâ€™s Disease. Molecules, 2017, 22, 1693.	1.7	26
51	Counteracting the effects of <scp>TNF</scp> receptorâ€1 has therapeutic potential in Alzheimer's disease. EMBO Molecular Medicine, 2018, 10, .	3.3	81
52	A Role for Cellular Prion Protein in Late-Onset Alzheimer's Disease: Evidence from Preclinical Studies. Journal of Neuroscience, 2018, 38, 2146-2148.	1.7	4
53	Motor coordination and synaptic plasticity deficits are associated with increased cerebellar activity of NADPH oxidase, CAMKII, and PKC at preplaque stage in the TgCRND8 mouse model of Alzheimer's disease. Neurobiology of Aging, 2018, 68, 123-133.	1.5	35
54	Characterization of a 3xTgâ€AD mouse model of Alzheimer's disease with the senescence accelerated mouse prone 8 (SAMP8) background. Synapse, 2018, 72, e22025.	0.6	16

#	Article	IF	Citations
55	Mesenchymal stem cells and cell-derived extracellular vesicles protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid-Î² oligomers. Journal of Biological Chemistry, 2018, 293, 1957-1975.	1.6	146
56	Thrombospondin-1 secreted by human umbilical cord blood-derived mesenchymal stem cells rescues neurons from synaptic dysfunction in Alzheimerâ€™s disease model. Scientific Reports, 2018, 8, 354.	1.6	57
57	Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, S313-S327.	1.2	31
58	The on-fibrillation-pathway membrane content leakage and off-fibrillation-pathway lipid mixing induced by 40-residue Î²-amyloid peptides in biologically relevant model liposomes. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1670-1680.	1.4	15
59	Metabolic Dysfunction in Alzheimerâ€™s Disease: From Basic Neurobiology to Clinical Approaches. Journal of Alzheimer's Disease, 2018, 64, S405-S426.	1.2	66
60	Cognitive benefits of lithium chloride in APP/PS1 mice are associated with enhanced brain clearance of Î²-amyloid. Brain, Behavior, and Immunity, 2018, 70, 36-47.	2.0	34
61	Î²APP Processing Drives Gradual Tau Pathology in an Age-Dependent Amyloid Rat Model of Alzheimerâ€™s Disease. Cerebral Cortex, 2018, 28, 3976-3993.	1.6	13
62	Amyloid Beta monomers regulate cyclic adenosine monophosphate response element binding protein functions by activating typeâ€1 insulinâ€like growth factor receptors in neuronal cells. Aging Cell, 2018, 17, e12684.	3.0	60
63	Crosstalk between endoplasmic reticulum stress and brain inflammation in Alzheimer's disease. Neuropharmacology, 2018, 136, 350-360.	2.0	61
64	The Blood brain-barrier and its role in Alzheimerâ€™s disease. Neuroforum, 2018, 24, A197-A205.	0.2	13
65	Die Blut-Hirn-Schranke und ihre Rolle in der AlzheimerÂâ€“ Krankheit. Neuroforum, 2018, 24, 287-296.	0.2	0
66	Molecular rotors report on changes in live cell plasma membrane microviscosity upon interaction with beta-amyloid aggregates. Soft Matter, 2018, 14, 9466-9474.	1.2	30
67	The Alzheimer's disease amyloid-Î² peptide affects the size-dynamics of raft-mimicking Lo domains in GM1-containing lipid bilayers. Soft Matter, 2018, 14, 9609-9618.	1.2	18
68	The Emerging Role of Altered Cerebellar Synaptic Processing in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 396.	1.7	38
69	Elevated Glutamate and Glutamine Levels in the Cerebrospinal Fluid of Patients With Probable Alzheimer's Disease and Depression. Frontiers in Psychiatry, 2018, 9, 561.	1.3	126
70	Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimerâ€™s disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimer's Research and Therapy, 2018, 10, 107.	3.0	80
71	Fucosterol inhibits the cholinesterase activities and reduces the release of pro-inflammatory mediators in lipopolysaccharide and amyloid-induced microglial cells. Journal of Applied Phycology, 2018, 30, 3261-3270.	1.5	27
72	Age-dependent Disturbances of Neuronal and Glial Protein Expression Profiles in Areas of Secondary Neurodegeneration Post-stroke. Neuroscience, 2018, 393, 185-195.	1.1	16

#	Article	IF	Citations
73	Polyphenols Derived from Lychee Seed Suppress AÎ² (1-42)-Induced Neuroinflammation. International Journal of Molecular Sciences, 2018, 19, 2109.	1.8	31
74	Intracerebroventricular injection of AÎ²1-42 combined with two-vessel occlusion accelerate Alzheimerâ€™s disease development in rats. Pathology Research and Practice, 2018, 214, 1583-1595.	1.0	11
75	Commentary: APP as a Mediator of the Synapse Pathology in Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2018, 12, 150.	1.8	3
76	Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. Frontiers in Neuroscience, 2018, 12, 37.	1.4	132
77	Alzheimer's Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits. Frontiers in Neuroscience, 2018, 12, 383.	1.4	168
78	Calprotectin influences the aggregation of metal-free and metal-bound amyloid-Î² by direct interaction. Metallomics, 2018, 10, 1116-1127.	1.0	10
79	Mangiferin and Morin Attenuate Oxidative Stress, Mitochondrial Dysfunction, and Neurocytotoxicity, Induced by Amyloid Beta Oligomers. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-13.	1.9	62
80	MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2018, 19, 1800.	1.8	32
81	Sex-Dependent Differences in Spontaneous Autoimmunity in Adult 3xTg-AD Mice. Journal of Alzheimer's Disease, 2018, 63, 1191-1205.	1.2	18
82	The Amyloid-Î² Oligomer Hypothesis: Beginning of the Third Decade. Journal of Alzheimer's Disease, 2018, 64, S567-S610.	1.2	572
83	AÎ² Oligomer Elimination Restores Cognition in Transgenic Alzheimerâ€™s Mice with Full-blown Pathology. Molecular Neurobiology, 2019, 56, 2211-2223.	1.9	29
84	Glucocorticoid receptors modulate dendritic spine plasticity and microglia activity in an animal model of Alzheimer's disease. Neurobiology of Disease, 2019, 132, 104568.	2.1	47
85	Endothelial Mitochondrial Dysfunction in Cerebral Amyloid Angiopathy and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 72, 1019-1039.	1.2	72
86	A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimerâ€™s Disease. Scientific Reports, 2019, 9, 9870.	1.6	35
87	Cellular Prion Protein as a Receptor of Toxic Amyloid-Î²42 Oligomers Is Important for Alzheimerâ€™s Disease. Frontiers in Cellular Neuroscience, 2019, 13, 339.	1.8	46
88	Challenges in the treatment of Alzheimerâ€™s disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors. Expert Review of Neurotherapeutics, 2019, 19, 623-652.	1.4	17
89	In Vivo Assessment of Retinal Biomarkers by Hyperspectral Imaging: Early Detection of Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 4492-4501.	1.7	37
90	Albumin Exchange in Alzheimer's Disease: Might CSF Be an Alternative Route to Plasma?. Frontiers in Neurology, 2019, 10, 1036.	1.1	15

#	Article	IF	Citations
91	Transplantation of Mesenchymal Stem Cells Improves Amyloid-Î² Pathology by Modifying Microglial Function and Suppressing Oxidative Stress. Journal of Alzheimer's Disease, 2019, 72, 867-884.	1.2	29
92	Amyloid Î² oligomers inhibit growth of human cancer cells. PLoS ONE, 2019, 14, e0221563.	1.1	22
93	Platelet-driven formation of interface peptide nano-network biosensor enabling a non-invasive means for early detection of Alzheimer's disease. Biosensors and Bioelectronics, 2019, 145, 111701.	5.3	19
94	The P2X7 receptor: a new therapeutic target in Alzheimerâ€™s disease. Expert Opinion on Therapeutic Targets, 2019, 23, 165-176.	1.5	37
95	Protein misfolding, aggregation and mechanism of amyloid cytotoxicity: An overview and therapeutic strategies to inhibit aggregation. International Journal of Biological Macromolecules, 2019, 134, 1022-1037.	3.6	79
96	Specific keratinase derived designer peptides potently inhibit AÎ² aggregation resulting in reduced neuronal toxicity and apoptosis. Biochemical Journal, 2019, 476, 1817-1841.	1.7	5
97	The role of APOE in transgenic mouse models of AD. Neuroscience Letters, 2019, 707, 134285.	1.0	37
98	Therapeutic Strategies for Alzheimerâ€™s Disease in the View of Diabetes Mellitus. Advances in Experimental Medicine and Biology, 2019, 1128, 227-248.	0.8	18
99	Physical & mental activities enhance the neuroprotective effect of vinpocetine & coenzyme Q10 combination against Alzheimer & bone remodeling in rats. Life Sciences, 2019, 229, 21-35.	2.0	19
100	Ultrastructural evidence of microglial heterogeneity in Alzheimerâ€™s disease amyloid pathology. Journal of Neuroinflammation, 2019, 16, 87.	3.1	73
101	Association of Cortical Î²-Amyloid Protein in the Absence of Insoluble Deposits With Alzheimer Disease. JAMA Neurology, 2019, 76, 818.	4.5	25
102	7-Pyrrolidinethoxy-4â€²-Methoxyisoflavone Prevents Amyloid Î²â€“Induced Injury by Regulating Histamine H3 Receptor-Mediated cAMP/CREB and AKT/GSK3Î² Pathways. Frontiers in Neuroscience, 2019, 13, 334.	1.4	7
103	Serotype b of Aggregatibacter actinomycetemcomitans triggers pro-inflammatory responses and amyloid beta secretion in hippocampal cells: a novel link between periodontitis and AlzheimerÂ´s disease?. Journal of Oral Microbiology, 2019, 11, 1586423.	1.2	35
104	Introductory Chapter: Eat, Learn, Remember. , 2019, , .		0
105	Synaptic Injury in the Thalamus Accompanies White Matter Injury in Hypoxia/Ischemia-Mediated Brain Injury in Neonatal Rats. BioMed Research International, 2019, 2019, 1-10.	0.9	10
106	Deceleration of the neurodegenerative phenotype in pyroglutamate-AÎ² accumulating transgenic mice by oral treatment with the AÎ² oligomer eliminating compound RD2. Neurobiology of Disease, 2019, 124, 36-45.	2.1	13
107	Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies. , 2019, 195, 186-198.		141
108	Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimerâ€™s models. Nature Medicine, 2019, 25, 165-175.	15.2	511

#	Article	IF	Citations
109	Proamyloidogenic effects of membrane type 1 matrix metalloproteinase involve MMPâ€2 and BACEâ€1 activities, and the modulation of APP trafficking. FASEB Journal, 2019, 33, 2910-2927.	0.2	25
110	Excitation-Energy-Dependent Molecular Beacon Detects Early Stage Neurotoxic AÎ² Aggregates in the Presence of Cortical Neurons. ACS Chemical Neuroscience, 2019, 10, 1240-1250.	1.7	8
111	Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimerâ€™s and Parkinsonâ€™s Diseases. CNS Drugs, 2019, 33, 209-223.	2.7	49
112	BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease. Medicinal Research Reviews, 2020, 40, 339-384.	5.0	177
113	In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimerâ€™s disease. Clinical Neurophysiology, 2020, 131, 88-95.	0.7	33
114	Destabilization of Î²â€amyloid aggregates by thrombin derived peptide: plausible role of thrombin in neuroprotection. FEBS Journal, 2020, 287, 2386-2413.	2.2	1
115	Adenovirus-Mediated Transduction of Insulin-Like Growth Factor 1 Protects Hippocampal Neurons from the Toxicity of AÎ² Oligomers and Prevents Memory Loss in an Alzheimer Mouse Model. Molecular Neurobiology, 2020, 57, 1473-1483.	1.9	19
116	Parallels between retinal and brain pathology and response to immunotherapy in old, lateâ€stage Alzheimer's disease mouse models. Aging Cell, 2020, 19, e13246.	3.0	32
117	From beta amyloid to altered proteostasis in Alzheimerâ€™s disease. Ageing Research Reviews, 2020, 64, 101126.	5.0	31
118	P.383 Effect of Î²-adrenergic antagonists on the risk of alzheimer's disease amongst hypertensive patients: a nation-wide cohort study. European Neuropsychopharmacology, 2020, 40, S219-S220.	0.3	1
119	The AÎ² aggregation modulator MRZ-99030 prevents and even reverses synaptotoxic effects of AÎ²1-42 on LTP even following serial dilution to a 500:1 stoichiometric excess of AÎ²1-42, suggesting a beneficial prion-like seeding mechanism. Neuropharmacology, 2020, 179, 108267.	2.0	5
120	Signaling via the p75 neurotrophin receptor facilitates amyloid-Î²-induced dendritic spine pathology. Scientific Reports, 2020, 10, 13322.	1.6	24
121	Plasma microRNAs biomarkers in mild cognitive impairment among patients with type 2 diabetes mellitus. PLoS ONE, 2020, 15, e0236453.	1.1	13
122	Guanosine Neuroprotection of Presynaptic Mitochondrial Calcium Homeostasis in a Mouse Study with Amyloid-Î² Oligomers. Molecular Neurobiology, 2020, 57, 4790-4809.	1.9	14
123	Computational modelling of TNFÎ± related pathways regulated by neuroinflammation, oxidative stress and insulin resistance in neurodegeneration. Applied Network Science, 2020, 5, .	0.8	3
124	Superparamagnetic iron oxide nanoparticles conjugated with AÎ² oligomer-specific scFv antibody and class A scavenger receptor activator show therapeutic potentials for Alzheimerâ€™s Disease. Journal of Nanobiotechnology, 2020, 18, 160.	4.2	24
125	The Role of Synaptic Dysfunction inÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 76, 49-62.	1.2	13
126	Molecular interactions between monoclonal oligomer-specific antibody 5E3 and its amyloid beta cognates. PLoS ONE, 2020, 15, e0232266.	1.1	0

#	Article	IF	Citations
127	Effects of N-Terminal Residues on the Assembly of Constrained Î²-Hairpin Peptides Derived from AÎ². Journal of the American Chemical Society, 2020, 142, 11593-11601.	6.6	12
128	Trehalose against Alzheimer's Disease: Insights into a Potential Therapy. BioEssays, 2020, 42, e1900195.	1.2	38
129	A mechanistic hypothesis for the impairment of synaptic plasticity by soluble AÎ² oligomers from Alzheimerâ€™s brain. Journal of Neurochemistry, 2020, 154, 583-597.	2.1	158
130	Ameliorating amyloid aggregation through osmolytes as a probable therapeutic molecule against Alzheimer's disease and type 2 diabetes. RSC Advances, 2020, 10, 12166-12182.	1.7	8
131	Sinomenine inhibits amyloid beta-induced astrocyte activation and protects neurons against indirect toxicity. Molecular Brain, 2020, 13, 30.	1.3	26
132	IGF-1R Inhibitor Ameliorates Neuroinflammation in an Alzheimerâ€™s Disease Transgenic Mouse Model. Frontiers in Cellular Neuroscience, 2020, 14, 200.	1.8	24
133	Amyloid-Î², tau, and the cholinergic system in Alzheimerâ€™s disease: seeking direction in a tangle of clues. Reviews in the Neurosciences, 2020, 31, 391-413.	1.4	56
134	Vaccines targeting the primary amino acid sequence and conformational epitope of amyloidâ€Î² had distinct effects on neuropathology and cognitive deficits in EAE/AD mice. British Journal of Pharmacology, 2020, 177, 2860-2871.	2.7	7
135	Activated Bone Marrow-Derived Macrophages Eradicate Alzheimer's-Related AÎ²42 Oligomers and Protect Synapses. Frontiers in Immunology, 2020, 11, 49.	2.2	32
136	Memory decline correlates with increased plasma cytokines in amyloid-beta (1â€“42) rat model of Alzheimerâ€™s disease. Neurobiology of Learning and Memory, 2020, 169, 107187.	1.0	13
137	Pharmacological Characterizations of anti-Dementia Memantine Nitrate via Neuroprotection and Vasodilation in Vitro and in Vivo. ACS Chemical Neuroscience, 2020, 11, 314-327.	1.7	9
138	Significant combination of AÎ² aggregation inhibitory and neuroprotective properties in silico, in vitro and in vivo by bis(propyl)-cognitin, a multifunctional anti-Alzheimerâ€™s agent. European Journal of Pharmacology, 2020, 876, 173065.	1.7	7
139	Insulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer's disease. Neuropharmacology, 2020, 171, 108115.	2.0	27
140	Oligomerization and Conformational Change Turn Monomeric Î²-Amyloid and Tau Proteins Toxic: Their Role in Alzheimerâ€™s Pathogenesis. Molecules, 2020, 25, 1659.	1.7	60
141	Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer's disease. Life Sciences, 2021, 264, 118627.	2.0	217
142	Soluble amyloid beta-containing aggregates are present throughout the brain at early stages of Alzheimerâ€™s disease. Brain Communications, 2021, 3, fcab147.	1.5	32
143	The plasminogen activating system in the pathogenesis of Alzheimerâ€™s disease. Neural Regeneration Research, 2021, 16, 1973.	1.6	18
144	Defining the Neuropathological Aggresome across in Silico, in Vitro, and ex Vivo Experiments. Journal of Physical Chemistry B, 2021, 125, 1974-1996.	1.2	5

#	Article	IF	Citations
145	Mitochondrial ubiquitin ligase alleviates Alzheimerâ€™s disease pathology via blocking the toxic amyloid-Î² oligomer generation. Communications Biology, 2021, 4, 192.	2.0	19
146	Correction of eIF2-dependent defects in brain protein synthesis, synaptic plasticity, and memory in mouse models of Alzheimerâ€™s disease. Science Signaling, 2021, 14, .	1.6	75
147	FNDC5/Irisin System in Neuroinflammation and Neurodegenerative Diseases: Update and Novel Perspective. International Journal of Molecular Sciences, 2021, 22, 1605.	1.8	61
148	Nutraceutical based SIRT3 activators as therapeutic targets in Alzheimer's disease. Neurochemistry International, 2021, 144, 104958.	1.9	20
149	Clusterin inhibits AÎ² 42 aggregation through a â€œstrawberry modelâ€•as detected by FRETâ€FCS. Journal of Neurochemistry, 2021, 158, 444-454.	2.1	2
150	Brain insulin, insulinâ€like growth factor 1 and glucagonâ€like peptide 1 signalling in Alzheimerâ€™s disease. Journal of Neuroendocrinology, 2021, 33, e12959.	1.2	35
151	Liver X Receptor Activation with an Intranasal Polymer Therapeutic Prevents Cognitive Decline without Altering Lipid Levels. ACS Nano, 2021, 15, 4678-4687.	7.3	17
152	The Oral-Gut-Brain AXIS: The Influence of Microbes in Alzheimerâ€™s Disease. Frontiers in Cellular Neuroscience, 2021, 15, 633735.	1.8	45
153	Sex differences in the IntelliCage and the Morris water maze in the APP/PS1 mouse model of amyloidosis. Neurobiology of Aging, 2021, 101, 130-140.	1.5	39
154	Adiponectin: a potential target for obesity-associated Alzheimerâ€™s disease. Metabolic Brain Disease, 2021, 36, 1565-1572.	1.4	10
155	From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimerâ€™s Disease. Current Neuropharmacology, 2021, 19, 832-867.	1.4	8
156	Calcium Dyshomeostasis in Alzheimerâ€™s Disease Pathogenesis. International Journal of Molecular Sciences, 2021, 22, 4914.	1.8	76
157	Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases. Biomolecules, 2021, 11, 767.	1.8	39
158	A Novel Selective PKR Inhibitor Restores Cognitive Deficits and Neurodegeneration in Alzheimer Disease Experimental Models. Journal of Pharmacology and Experimental Therapeutics, 2021, 378, 262-275.	1.3	3
159	Early Effects of the Soluble Amyloid Î²25-35 Peptide in Rat Cortical Neurons: Modulation of Signal Transduction Mediated by Adenosine and Group I Metabotropic Glutamate Receptors. International Journal of Molecular Sciences, 2021, 22, 6577.	1.8	9
160	Ð'Ð»Ð¸Ñ½Ð¸Ðµ Ð³Ð»Ð¾Ð±Ð°Ð»ÑŒÐ½Ð¾Ð¹ Ð¸ÑˆÐµÐ¼Ð¸Ð¸ Ð³Ð¾Ð»Ð¾Ð²Ð½Ð¾Ð³Ð¾ Ð¼Ð¾Ð·Ð³Ð° Ð¸ Ð¿Ð°	2.0	0
161	Effect of Global Brain Ischemia on Amyloid Precursor Protein Metabolism and Expression of Amyloid-Degrading Enzymes in Rat Cortex: Role in Pathogenesis of Alzheimerâ€™s Disease. Biochemistry (Moscow), 2021, 86, 680-692.	0.7	6
162	Importance of Hydrogen Bonding: Structureâ€“Activity Relationships of Ruthenium(III) Complexes with Pyridine-Based Ligands for Alzheimerâ€™s Disease Therapy. Journal of Medicinal Chemistry, 2021, 64, 10124-10138.	2.9	21

#	Article	IF	Citations
163	Potential therapeutic natural products against Alzheimer's disease with Reference of Acetylcholinesterase. Biomedicine and Pharmacotherapy, 2021, 139, 111609.	2.5	54
164	Age-Related Transcriptional Deregulation of Genes Coding Synaptic Proteins in Alzheimer's Disease Murine Model: Potential Neuroprotective Effect of Fingolimod. Frontiers in Molecular Neuroscience, 2021, 14, 660104.	1.4	10
165	HSF-1 mediated combined ginsenosides ameliorating Alzheimerâ€™s disease like symptoms in Caernorhabditis elegans. Nutritional Neuroscience, 2022, 25, 2136-2148.	1.5	9
166	Importance of extracellular vesicle secretion at the bloodâ€“cerebrospinal fluid interface in the pathogenesis of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2021, 9, 143.	2.4	30
168	Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimerâ€™s Disease. ACS Medicinal Chemistry Letters, 2021, 12, 1389-1395.	1.3	19
169	Long-term depression links amyloid-Î² to the pathological hyperphosphorylation of tau. Cell Reports, 2021, 36, 109638.	2.9	16
170	Cerebrospinal Fluid Neurotransmitters, Cytokines, and Chemokines in Alzheimerâ€™s and Lewy Body Diseases. Journal of Alzheimer's Disease, 2021, 82, 1067-1074.	1.2	13
171	Metformin a Potential Pharmacological Strategy in Late Onset Alzheimerâ€™s Disease Treatment. Pharmaceuticals, 2021, 14, 890.	1.7	19
172	Oligomeric and Fibrillar Species of AÎ²42 Diversely Affect Human Neural Stem Cells. International Journal of Molecular Sciences, 2021, 22, 9537.	1.8	4
173	Flavanonol Glycosides from the Stems of Myrsine seguinii and Their Neuroprotective Activities. Pharmaceuticals, 2021, 14, 911.	1.7	1
174	Depichering the Effects of Astragaloside IV on AD-Like Phenotypes: A Systematic and Experimental Investigation. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-21.	1.9	14
175	Distinct types of amyloidâ€Î² oligomers displaying diverse neurotoxicity mechanisms in Alzheimer's disease. Journal of Cellular Biochemistry, 2021, 122, 1594-1608.	1.2	15
176	Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: Tales of a vicious cycle. , 2022, 231, 107988.		59
177	Exploring amyloid oligomers with peptide model systems. Current Opinion in Chemical Biology, 2021, 64, 106-115.	2.8	23
178	Mechanistic insights into procyanidins as therapies for Alzheimer's disease: A review. Journal of Functional Foods, 2021, 86, 104683.	1.6	11
179	Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting AÎ²oâ€“PrP^Cbinding and downstream pathways. Chemical Science, 2021, 12, 3768-3785.	3.7	6
180	Differential effects of chronic immunosuppression on behavioral, epigenetic, and Alzheimerâ€™s disease-associated markers in 3xTg-AD mice. Alzheimer's Research and Therapy, 2021, 13, 30.	3.0	7
181	A conformation-specific antibody against oligomeric Î²-amyloid restores neuronal integrity in a mouse model of Alzheimer's disease. Journal of Biological Chemistry, 2021, 296, 100241.	1.6	4

#	Article	IF	Citations
182	Oxidative Stress in Alzheimerâ€™s Disease: Molecular Hallmarks of Underlying Vulnerability. , 2019, , 91-115.		26
183	The aroylhydrazone INHHQ prevents memory impairment induced by Alzheimerâ€™s-linked amyloid-Î² oligomers in mice. Behavioural Pharmacology, 2020, 31, 738-747.	0.8	9
184	Effect of C-phycocyanin on HDAC3 and miRNA-335 in Alzheimerâ€™s disease. Translational Neuroscience, 2020, 11, 161-172.	0.7	11
185	GSK3Î² Impairs KIF1A Transport in a Cellular Model of Alzheimerâ€™s Disease but Does Not Regulate Motor Motility at S402. ENeuro, 2020, 7, ENEURO.0176-20.2020.	0.9	9
186	AÎ² Plaques. Free Neuropathology, 2020, 1, .	2.4	21
187	Knockout of p75 neurotrophin receptor attenuates the hyperphosphorylation of Tau in pR5 mouse model. Aging, 2019, 11, 6762-6791.	1.4	17
188	Heterogeneity in brain distribution of activated microglia and astrocytes in a rat ischemic model of Alzheimerâ€™s disease after 2 years of survival. Aging, 2020, 12, 12251-12267.	1.4	66
189	Assessing amyloid-Î², tau, and glial features in Lothian Birth Cohort 1936 participants post-mortem. Matters, 0, , .	1.0	2
190	The Amyloid Cascade Hypothesis in Alzheimerâ€™s Disease: Itâ€™s Time to Change Our Mind. Current Neuropharmacology, 2017, 15, 926-935.	1.4	253
191	The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. Frontiers in Endocrinology, 2020, 11, 25.	1.5	1,235
192	Obesity and Diabetes Mediated Chronic Inflammation: A Potential Biomarker in Alzheimerâ€™s Disease. Journal of Personalized Medicine, 2020, 10, 42.	1.1	29
193	Expression levels of the Î±7 nicotinic acetylcholine receptor in the brains of patients with Alzheimer's disease and their effect on synaptic proteins in SH-SY5Y cells. Molecular Medicine Reports, 2020, 22, 2063-2075.	1.1	23
194	The Drosophila adult neuromuscular junction as a model for unravelling amyloid peptide influence on synapse dynamics. Neural Regeneration Research, 2017, 12, 1987.	1.6	2
195	Distinguishing normal brain aging from the development of Alzheimer's disease: inflammation, insulin signaling and cognition. Neural Regeneration Research, 2018, 13, 1719.	1.6	59
196	Physiological and pathological effects of amyloid-Î² species in neural stem cell biology. Neural Regeneration Research, 2019, 14, 2035.	1.6	22
197	Treatment with Bifidobacteria can suppress AÎ² accumulation and neuroinflammation in APP/PS1 mice. PeerJ, 2020, 8, e10262.	0.9	12
198	Oat Extract Avenanthramide-C Reverses Hippocampal Long-Term Potentiation Decline in Tg2576 Mice. Molecules, 2021, 26, 6105.	1.7	3
199	Tetrahydrocurcumin Has Similar Anti-Amyloid Properties as Curcumin:Â In Vitro Comparative Structure-Activity Studies. Antioxidants, 2021, 10, 1592.	2.2	11

#	Article	IF	Citations
200	Inhalational Anesthetics Do Not Deteriorate Amyloid-Î²-Derived Pathophysiology in Alzheimerâ€™s Disease: Investigations on the Molecular, Neuronal, and Behavioral Level. Journal of Alzheimer's Disease, 2021, 84, 1193-1218.	1.2	1
202	Amyloid beta 1â€“42-induced animal model of dementia. , 2020, , 865-880.		1
203	Glia: A major player in glutamateâ€“GABA dysregulationâ€mediated neurodegeneration. Journal of Neuroscience Research, 2021, 99, 3148-3189.	1.3	29
205	Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease. American Journal of Neurodegenerative Disease, 2016, 5, 1-28.	0.1	14
206	Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease in focal cerebral ischemic rats. American Journal of Neurodegenerative Disease, 2016, 5, 102-30.	0.1	24
207	Advances in Proteasome Enhancement by Small Molecules. Biomolecules, 2021, 11, 1789.	1.8	13
208	Synaptic dysfunction in early phases of Alzheimer's Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, 184, 417-438.	1.0	27
209	Reduced mitochondria membrane potential and lysosomal acidification are associated with decreased oligomeric AÎ² degradation induced by hyperglycemia: A study of mixed glia cultures. PLoS ONE, 2022, 17, e0260966.	1.1	9
210	A Disulfide-Stabilized AÎ² that Forms Dimers but Does Not Form Fibrils. Biochemistry, 2022, 61, 252-264.	1.2	4
211	Effects of amyloid-Î² on protein SUMOylation and levels of mitochondrial proteins in primary cortical neurons. IBRO Neuroscience Reports, 2022, 12, 142-148.	0.7	2
213	An Essential Role for Alzheimerâ€™s-Linked Amyloid Beta Oligomers in Neurodevelopment: Transient Expression of Multiple Proteoforms during Retina Histogenesis. International Journal of Molecular Sciences, 2022, 23, 2208.	1.8	5
214	Disruption of the grid cell network in a mouse model of early Alzheimerâ€™s disease. Nature Communications, 2022, 13, 886.	5.8	27
215	Aducanumab Therapy to Treat Alzheimerâ€™s Disease: A Narrative Review. International Journal of Alzheimer's Disease, 2022, 2022, 1-10.	1.1	25
216	Effects of heparan sulfate from porcine mucosa on AÎ²1â€“42-induced neurotoxicity in vitro and in vivo. International Journal of Biological Macromolecules, 2022, 206, 823-836.	3.6	0
217	VEGF and its role in the treatment of Diabetes and Alzhiemerâ€™s Disease. , 2021, , .		0
218	Ellagic Acid Modulates the Amyloid Precursor Protein Gene via Superoxide Dismutase Regulation in the Entorhinal Cortex in an Experimental Alzheimerâ€™s Model. Cells, 2021, 10, 3511.	1.8	7
219	Alzheimerâ€™s disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis. Nature Aging, 2022, 2, 60-73.	5.3	12
226	ACU193: An Immunotherapeutic Poised to Test the Amyloid Î² Oligomer Hypothesis of Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2022, 16, 848215.	1.4	17

#	Article	IF	Citations
227	Amyloid-beta targeted therapeutic approaches for Alzheimerâ€™s disease: long road ahead. Current Drug Targets, 2022, 23, .	1.0	6
228	Site specific NMR characterization of abeta-40 oligomers cross seeded by abeta-42 oligomers. Chemical Science, 2022, 13, 8526-8535.	3.7	8
230	LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions. Molecular Neurodegeneration, 2022, 17, .	4.4	12
231	Beta-Site Amyloid Precursor Protein-Cleaving Enzyme Inhibition Partly Restores Sevoflurane-Induced Deficits on Synaptic Plasticity and Spine Loss. International Journal of Molecular Sciences, 2022, 23, 6637.	1.8	0
232	Aberrant Synaptic Pruning in CNS Diseases: A Critical Player in HIV-Associated Neurological Dysfunction?. Cells, 2022, 11, 1943.	1.8	3
233	New Insights into Neuroinflammation Involved in Pathogenic Mechanism of Alzheimerâ€™s Disease and Its Potential for Therapeutic Intervention. Cells, 2022, 11, 1925.	1.8	29
234	Model scenarios for cell cycle re-entry in Alzheimer's disease. IScience, 2022, 25, 104543.	1.9	3
235	A Novel Multifunctional 5,6-Dimethoxy-Indanone-Chalcone-Carbamate Hybrids Alleviates Cognitive Decline in Alzheimerâ€™s Disease by Dual Inhibition of Acetylcholinesterase and Inflammation. Frontiers in Aging Neuroscience, 0, 14, .	1.7	1
236	AÎ²₄₂ oligomers can seed the fibrillization of AÎ²₄₀ peptides. Journal of the Chinese Chemical Society, 2022, 69, 1318-1325.	0.8	2
237	Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimerâ€™s disease. Natural Products and Bioprospecting, 2022, 12, .	2.0	4
238	Cucurbit[7]uril Macrocyclic Sensors for Optical Fingerprinting: Predicting Protein Structural Changes to Identifying Disease-Specific Amyloid Assemblies. Journal of the American Chemical Society, 2022, 144, 14363-14379.	6.6	19
239	A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer's Disease Mice. Neurotherapeutics, 2022, 19, 1588-1602.	2.1	13
240	Targeting NMDA Receptors at the Neurovascular Unit: Past and Future Treatments for Central Nervous System Diseases. International Journal of Molecular Sciences, 2022, 23, 10336.	1.8	16
241	Natural Therapeutics in Aid of Treating Alzheimerâ€™s Disease: A Green Gateway Toward Ending Quest for Treating Neurological Disorders. Frontiers in Neuroscience, 0, 16, .	1.4	19
243	Novel Anti-Neuroinflammatory Properties of a Thiosemicarbazoneâ€“Pyridylhydrazone Copper(II) Complex. International Journal of Molecular Sciences, 2022, 23, 10722.	1.8	5
244	Mechanisms of Influence of Intestinal Microbiota on the Processes of Aging of the CNS and the Formation of Cognitive Disorders in Alzheimerâ€™s Disease. Psychiatry, 2022, 20, 98-111.	0.2	2
246	Synaptogenic effect of APP -Swedish mutation in familial Alzheimerâ€™s disease. Science Translational Medicine, 2022, 14, .	5.8	29
247	Microglia and Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 12990.	1.8	28

#	Article	IF	Citations
248	Unveiling the Potential of Polyphenols as Anti-Amyloid Molecules in Alzheimerâ€™s Disease. Current Neuropharmacology, 2023, 21, 787-807.	1.4	1
249	The link between periodontitis and Alzheimer's disease â€“ emerging clinical evidence. , 2023, 3, 100062.		3
250	APC/C-Cdh1-targeted substrates as potential therapies for Alzheimerâ€™s disease. Frontiers in Pharmacology, 0, 13, .	1.6	2
251	AÎ²-Targeting Bifunctional Chelators (BFCs) for Potential Therapeutic and PET Imaging Applications. International Journal of Molecular Sciences, 2023, 24, 236.	1.8	3
253	AÎ²42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimerâ€™s disease brain extracts. Alzheimer's Research and Therapy, 2022, 14, .	3.0	3
254	Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimerâ€™s disease. GeroScience, 2023, 45, 1095-1113.	2.1	14
255	AÎ²-oligomers: A potential therapeutic target for Alzheimer's disease. International Journal of Biological Macromolecules, 2023, 239, 124231.	3.6	15
256	Defective proteostasis in Alzheimerâ€™s disease. Ageing Research Reviews, 2023, 85, 101862.	5.0	9
257	Protective Potential of Î²-Hydroxybutyrate against Glucose-Deprivation-Induced Neurotoxicity Involving the Modulation of Autophagic Flux and the Monomeric AÎ² Level in Neuro-2a Cells. Biomedicines, 2023, 11, 698.	1.4	2
258	Oxytocin attenuates microglial activation and restores social and non-social memory in APP/PS1 Alzheimer model mice. IScience, 2023, 26, 106545.	1.9	6
259	Influence of amyloid beta on impulse spiking of isolated hippocampal neurons. Frontiers in Cellular Neuroscience, 0, 17, .	1.8	0